Positive Phase 2 Data for PRGN-2012 Raises Precigen Shares Target
Monday, 3 June 2024, 12:26
Precigen Shares Target Raised
The latest phase 2 data for PRGN-2012 has led to a positive revision of the price target for Precigen shares. Analysts are optimistic about the results and are revising their forecasts accordingly.
Promising Results for PRGN-2012
The data from phase 2 trials of PRGN-2012 have shown promising outcomes, driving increased interest from investors and analysts. The positive results indicate a potential growth opportunity for Precigen in the market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.